《世界卫生组织耐药结核病治疗指南（2016年更新版）：在韩国的适用性》
WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea.
作者信息
Jeon Doosoo
机构信息
Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
出版信息
Tuberc Respir Dis (Seoul). 2017 Oct;80(4):336-343. doi: 10.4046/trd.2017.0049. Epub 2017 Sep 1.
Abstract
Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are intended to improve detection rate and treatment outcome for MDR-TB through novel, rapid molecular testing and shorter treatment regimens. Key changes include the introduction of a new, shorter MDR-TB treatment regimen, a new classification of medicines and updated recommendations for the conventional MDR-TB regimen. This paper will review these key changes and discuss the potential issues with regard to the implementation of these guidelines in South Korea.
摘要
尽管全球结核病控制取得了进展，但耐多药结核病（MDR-TB）患者的疾病负担和治疗结果几乎没有变化。2016年，世界卫生组织发布了耐多药结核病管理新指南。这些指南旨在通过新型快速分子检测和更短的治疗方案提高耐多药结核病的检出率和治疗效果。主要变化包括引入新的、更短的耐多药结核病治疗方案、药物新分类以及传统耐多药结核病治疗方案的更新建议。本文将回顾这些主要变化，并讨论在韩国实施这些指南可能存在的问题。
相似文献
1
WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea.
Tuberc Respir Dis (Seoul). 2017 Oct;80(4):336-343. doi: 10.4046/trd.2017.0049. Epub 2017 Sep 1.
2
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
4
Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
J Korean Med Sci. 2017 Apr;32(4):636-641. doi: 10.3346/jkms.2017.32.4.636.
6
Treatment of multidrug-resistant tuberculosis in Thailand.
Chemotherapy. 1996;42 Suppl 3:10-5; discussion 30-3. doi: 10.1159/000239508.
7
Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
Respirology. 2018 Jan;23(1):36-45. doi: 10.1111/resp.13143. Epub 2017 Aug 29.
8
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
J Assoc Physicians India. 2006 Mar;54:219-34.
9
Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Microbiol Spectr. 2017 Mar;5(2). doi: 10.1128/microbiolspec.TNMI7-0042-2017.
10
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.
Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.
引用本文的文献
1
Retrospective epidemiological analysis of pulmonary tuberculosis in the older adult and characterization of rifampicin resistance-associated mutations in Nantong City, China (2014-2023).
Front Public Health. 2025 May 26;13:1577211. doi: 10.3389/fpubh.2025.1577211. eCollection 2025.
2
Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2127-2150. doi: 10.1007/s00210-024-03466-0. Epub 2024 Oct 8.
3
A Series of Spiropyrimidinetriones that Enhances DNA Cleavage Mediated by Gyrase.
ACS Infect Dis. 2023 Mar 10;9(3):706-715. doi: 10.1021/acsinfecdis.3c00012. Epub 2023 Feb 20.
4
Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?
Children (Basel). 2022 Jul 27;9(8):1120. doi: 10.3390/children9081120.
5
Synthesis, computational studies, antimycobacterial and antibacterial properties of pyrazinoic acid-isoniazid hybrid conjugates.
RSC Adv. 2019 Jul 1;9(35):20450-20462. doi: 10.1039/c9ra03380g. eCollection 2019 Jun 25.
6
Importance of Public-Private Mix Collaboration in Tuberculosis Control: It Is Also Valuable in Patients with Multidrug-Resistant Tuberculosis.
Tuberc Respir Dis (Seoul). 2021 Jan;84(1):85-86. doi: 10.4046/trd.2020.0152. Epub 2020 Dec 4.
7
Clofazimine enhances the efficacy of BCG revaccination via stem cell-like memory T cells.
PLoS Pathog. 2020 May 21;16(5):e1008356. doi: 10.1371/journal.ppat.1008356. eCollection 2020 May.
8
Uncovering the Resistance Mechanism of to Rifampicin Due to RNA Polymerase H451D/Y/R Mutations From Computational Perspective.
Front Chem. 2019 Dec 3;7:819. doi: 10.3389/fchem.2019.00819. eCollection 2019.
9
Curcumin Nanoparticles Enhance Mycobacterium bovis BCG Vaccine Efficacy by Modulating Host Immune Responses.
Infect Immun. 2019 Oct 18;87(11). doi: 10.1128/IAI.00291-19. Print 2019 Nov.
10
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
本文引用的文献
1
Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
J Korean Med Sci. 2017 Apr;32(4):636-641. doi: 10.3346/jkms.2017.32.4.636.
2
Performance of the BacT Alert 3D System Versus Solid Media for Recovery and Drug Susceptibility Testing of in a Tertiary Hospital in Korea.
Tuberc Respir Dis (Seoul). 2016 Oct;79(4):282-288. doi: 10.4046/trd.2016.79.4.282. Epub 2016 Oct 5.
3
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE.
4
Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.
Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1.
5
Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB.
Clin Infect Dis. 2016 Jul 15;63(2):214-20. doi: 10.1093/cid/ciw276. Epub 2016 May 8.
6
Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes.
Ann Am Thorac Soc. 2016 Mar;13(3):364-70. doi: 10.1513/AnnalsATS.201510-690BC.
7
Issues Related to the Updated 2014 Korean Guidelines for Tuberculosis.
Tuberc Respir Dis (Seoul). 2016 Jan;79(1):1-4. doi: 10.4046/trd.2016.79.1.1. Epub 2015 Dec 31.
8
Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
PLoS Med. 2015 Dec 29;12(12):e1001932. doi: 10.1371/journal.pmed.1001932. eCollection 2015 Dec.
9
Evaluation of the GenoType® MTBDRsl assay in Korean patients with MDR or XDR tuberculosis.
Infect Dis (Lond). 2016;48(5):361-6. doi: 10.3109/23744235.2015.1125999. Epub 2015 Dec 22.
10
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Eur Respir J. 2015 Oct;46(4):887-93. doi: 10.1183/13993003.00432-2015.
Zotero 插件